The Roche group has agreed to pay €130 million upfront to acquire 100% of a Heidelberg-based company which is developing in vitro diagnostics for the early detection and diagnosis of cervical cancer. The company is Mtm Laboratories AG. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
